EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma

Molecular Cancer Research

Volumn 7, Issue 2, 2009, Pages 189-198

  Seeliger, Hendrik ^a   Camaj, Peter ^a   Ischenko, Ivan ^a   Kleespies, Axel ^a   De Toni, Enrico N ^a   Thieme, Susanne E ^b   Blum, Helmut ^b   Assmann, Gerald ^a   Jauch, Karl Walter ^a   Bruns, Christiane J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR CONTAINING FIBULIN LIKE EXTRACELLULAR MATRIX PROTEIN 1; FIBULIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MESSENGER RNA; PROPIDIUM IODIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MICROARRAY ANALYSIS; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA HYBRIDIZATION; SERUM; STAINING; STARVATION; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 61349114335     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0132     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinibin cancer treatment. Ann Oncol 2007;18 Suppl 6:vi35-41.
3. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23: 8033-40.
4. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007;25: 4787-92.
5. Kobayashi N, Kostka G, Garbe JH, et al. A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J Biol Chem 2007;282:11805-16.
6. Gallagher WM, Currid CA, Whelan LC. Fibulins and cancer: friend or foe? Trends Mol Med 2005;11:336-40.
7. Pupa SM, Argraves WS, Forti S, et al. Immunological and pathobiological roles offibulin-1 in breast cancer. Oncogene 2004;23:2153-60.
8. Pupa SM, Giuffre S, Castiglioni F, et al. Regulation of breast cancerresponse to chemotherapy by fibulin-1. Cancer Res 2007;67:4271 -7.
9. Yi CH, Smith DJ, West WW, Hollingsworth MA. Loss of fibulin-2 expression is associated with breast cancerprogression. Am J Pathol 2007;170:1535-45.
10. Gallagher WM, Greene LM, Ryan MP, et al. Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Lett 2001;489:59-66.
11. Lee YH, Albig AR, Maryann R, Schiemann BJ, Schiemann WP. Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-β in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis 2008;29:2243 -51.
12. Marmorstein LY, Munier FL, Arsenijevic Y, et al. Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration. Proc Natl Acad Sci U S A 2002;99:13067-72.
13. Stone EM, Lotery AJ, Munier FL, et al. A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet 1999;22:199-202.
14. Harding HP, Calfon M, Urano F, Novoa I, Ron D. Transcriptional and translational control in the mammalian unfolded protein response. Annu Rev Cell Dev Biol 2002;18:575-99.
15. Roybal CN, Marmorstein LY, Vander Jagt DL, Abcouwer SF. Aberrant accumulation of fibulin-3 in the endoplasmic reticulum leads to activation of the unfolded protein response and VEGF expression. Invest Ophthalmol Vis Sci 2005;46:3973-9.
16. McLaughlin PJ, Bakall B, Choi J, et al. Lack of fibulin-3 causes early aging and herniation, but not maculardegeneration in mice. Hum Mol Genet 2007;16: 3059-70.
17. Lecka-Czernik B, Lumpkin CK, Jr., Goldstein S. An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis. Mol Cell Biol 1995;15:120-8.
18. Albig AR, Neil JR, Schiemann WP. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006;66:2621-9.
19. Schiemann WP, Blobe GC, Kalume DE, Pandey A, Lodish HF. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor- β and affects protein kinase cascades. J Biol Chem 2002;277:27367 -77.
20. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999;1:50 -62.
21. Esposito I, Menicagli M, Funel N, et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 2004;57:630-6.
22. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Mark Evers B. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 2004;239:763-9; discussion 9-71.
23. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17:279-84.
24. Nakamura T, Fidler IJ, Coombes KR. Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment. Cancer Res 2007;67:139-48.
25. Chen R, Brentnall TA, Pan S, et al. Quantitative proteomic analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics 2007;6:1331-42.
26. Chen R, Pan S, Cooke K, et al. Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 2007;34:70-9.
27. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:726-31.
28. Blackburn J, Tarttelin EE, Gregory-Evans CY, Moosajee M, Gregory-Evans K. Transcriptional regulation and expression of the dominant drusen gene FBLN3 (EFEMP1) in mammalian retina. Invest Ophthalmol Vis Sci 2003;44:4613-21.
29. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518 -24.
30. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003;9:407 -15.
31. Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor- containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem 2004;279:30469 -73.
32. Bell SE, Mavila A, Salazar R, et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci 2001;114:2755 -73.
33. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006;5:1387 -95.
34. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3:1309 -16.
35. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M. Concomitant over- expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000;85:27 -34.
36. Tang RF, Wang SX, Peng L, et al. Expression of vascular endothelial growth factors A and C inhuman pancreatic cancer. World J Gastroenterol 2006;12:280-6.
37. Yue W, Dacic S, Sun Q, et al. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 2007;13:4336 -44.
38. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.